Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
1. A method of treating a mammal suffering from a disease, condition, or disorder selected from the group consisting of a psychotropic disorder, an anxiety disorder, a generalized anxiety disorder, depression, a post-traumatic stress disorder, an obsessive-compulsive disorder, a panic disorder, a hot flash, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, a psychiatric disorder, a premenstrual dysphoric disorder, a social phobia, a social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and premature ejaculation comprising administering to said mammal a therapeutically effective amount of a compound having structural Formula 1
or a pharmaceutically acceptable salt thereof, wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 are independently selected from the group consisting of hydrogen and deuterium;
R 19 , R 20 , and R 21 are independently selected from the group consisting of —CH 3 and —CD 3 ;
provided that said compound of Formula 1 contains at least three deuterium atoms; and
provided that deuterium enrichment in said compound of Formula 1 is at least about 1%.
2. The method of claim 1 , wherein said disease, condition, or disorder is depression.
3. The method of claim 1 , wherein the compound of Formula I affects decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound.
4. The method of claim 1 , wherein the compound of Formula I affects increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound.
5. The method of claim 1 , wherein the compound of Formula I affects decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound.
6. The method of claim 1 , wherein the compound of Formula I affects a decreased metabolism by at least one polymorphically-expressed cytochrome P 450 isoform in mammalian subjects per dosage unit thereof as compared to the non-isotopically enriched compound.
7. The method of claim 6 , wherein said cytochrome P 450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
8. The method of claim 1 , wherein the compound of Formula I affects a decreased inhibition of at least one cytochrome P 450 isoform in mammalian subjects per dosage unit thereof as compared to the non-isotopically enriched compound.
9. The method of claim 8 , wherein said cytochrome P 450 isoform is selected from the group consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4×1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, and CYP51.
10. The method of claim 1 , wherein the compound of Formula I elicits an improved clinical effect during the treatment in said mammal per dosage unit thereof as compared to the non-isotopically enriched compound.
11. The method of claim 10 , wherein the said improved clinical effect comprises an effect selected from the group consisting of accelerated rate of healing, accelerated rate of symptom relief, improved patient compliance, and reduced substance abuse withdrawal symptomology during the treatment.
12. A method of treating a mammal for a drug addiction comprising co-administering a first component and a second component, wherein said first component comprises a therapeutically effective amount of a compound of Formula 1, and said second component comprises a therapeutically effective amount of an opioid antagonist, said compound having structural Formula 1
or a pharmaceutically acceptable salt thereof, wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , and R 18 are independently selected from the group consisting of hydrogen and deuterium;
R 19 , R 20 , and R 21 are independently selected from the group consisting of —CH 3 and —CD 3 ;
provided that said compound of Formula 1 contains at least three deuterium atoms; and
provided that deuterium enrichment in said compound of Formula 1 is at least about 1%.
13. The method of claim 12 , wherein said opioid antagonist is selected from the group consisting of nalmefene, naltrexone, and naloxone.
14. The method of claim 12 , wherein said drug addiction is selected from the group consisting of tobacco addiction, alcohol addiction, marijuana addiction, and cocaine addiction.
15. The method of claim 12 , wherein said first component elicits an improved clinical effect for the treatment of a drug addiction, as compared to the non-isotopically enriched analog of the first component.
16. The method of claim 15 , wherein said improved clinical effect is selected from the group consisting of an accelerated rate of healing, an accelerated rate of symptom relief, improved patient compliance, and reduced substance abuse withdrawal symptomatology during the treatment.
17. The method of claim 1 , wherein said compound of Formula 1 has the structural formula:
or a pharmaceutically acceptable salt thereof.
18. The method of claim 17 , wherein said compound of Formula 1 is a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the (−)-enantiomer.
19. The method of claim 17 , wherein said compound of Formula 1 is a mixture of about 90% or more by weight of the (−)-enantiomer and about 10% or less by weight of the (+)-enantiomer.
20. The method of claim 17 , wherein said compound of Formula 1 is a hydrochloride salt.
21. The method of claim 20 , wherein said hydrochloride salt is a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the (−)-enantiomer.
22. The method of claim 20 , wherein said hydrochloride salt is a mixture of about 90% or more by weight of the (−)-enantiomer and about 10% or less by weight of the (+)-enantiomer.
23. The method of claim 12 , wherein said compound of Formula 1 has the structural formula:
or a pharmaceutically acceptable salt thereof.
24. The method of claim 23 , wherein said compound of Formula 1 is a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the (−)-enantiomer.
25. The method of claim 23 , wherein said compound of Formula 1 is a mixture of about 90% or more by weight of the (−)-enantiomer and about 10% or less by weight of the (+)-enantiomer.
26. The method of claim 23 , wherein said compound of Formula 1 is a hydrochloride salt.
27. The method of claim 26 , wherein said hydrochloride salt is a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the (−)-enantiomer.
28. The method of claim 26 , wherein said hydrochloride salt is a mixture of about 90% or more by weight of the (−)-enantiomer and about 10% or less by weight of the (+)-enantiomer.